Use of Infliximab or Adalimumab in Biologic-Naive Patients With Inflammatory Bowel Disease: Study of Patient Reported Outcomes in IBD Partners

被引：0
|
作者：
Weaver, Kimberly [1 ]
Curtis, Jeffrey [2 ]
Beukelman, Tim [2 ]
Zhang, Xian [1 ]
Kappelman, Michael [1 ]
Long, Millie [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC 27515 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2019年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P105
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [41] Infliximab population pharmacokinetic modelling in patients with Inflammatory Bowel Disease (IBD): Patient factors influencing infliximab pharmacokinetics
    Guardiola, J.
    Rodriguez-Alonso, L.
    Santacana, E.
    Padulles, N.
    Colom, H.
    Padulles, A.
    Arajol, C.
    Ruiz-Cerulla, A.
    Cobo, S.
    Bas, J.
    Climent, J.
    Morandeira, F.
    Rodriguez-Moranta, F.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S306 - S307
  • [42] Thiopurine Use and Persistence on Infliximab Therapy for Inflammatory Bowel Disease (IBD)
    Haynes, Kevin
    Curtis, Jeffery R.
    Chen, Lang
    Osterman, Mark T.
    Saag, Ken G.
    Lewis, James D.
    GASTROENTEROLOGY, 2011, 140 (05) : S781 - S781
  • [43] Thiopurine Use and Persistence on Infliximab Therapy for Inflammatory Bowel Disease (IBD)
    Haynes, Kevin
    Lewis, James D.
    Osterman, Mark T.
    Chen, Lang
    Kenneth, Saag
    Curtis, Jeffery R.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S71 - S71
  • [44] Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting
    Strober, Bruce
    Patil, Dhaval
    McLean, Robert R.
    Moore-Clingenpeel, Melissa
    Guo, Ning
    Levi, Eugenia
    Lebwohl, Mark
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (08) : 3178 - 3187
  • [45] Patients' Perspective on Biologic Use and Route of Administration in Inflammatory Bowel Disease: A Single Center Survey Evaluation of Patient-reported Outcomes
    Yen Truong
    Haidar, Bayaan
    Zhu, Kehao
    Afzali, Anita
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S427 - S428
  • [46] Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab
    Khan, M.
    Heetun, Z.
    Moloney, J.
    Courtney, G.
    Aftab, A. R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S73 - S74
  • [47] Efficacy of Infliximab in Biologic-Experienced Patients with Inflammatory Bowel Disease: A Retrospective Study
    Chaves, C. Borges
    Corveira, J.
    Ferreira, A. M.
    Lopes, S.
    Mendes, S.
    Ferreira, M.
    Figueiredo, P. Narra
    Portela, F.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i412 - i412
  • [48] Changes in Patient-Reported Outcomes With Vedolizumab Therapy in Patients With Inflammatory Bowel Diseases (IBD)
    Long, Millie D.
    Martin, Christopher
    Chen, Wenli
    Jaeger, Elizabeth
    Barocas, Morris
    Luo, Michelle
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S342 - S342
  • [49] DELAYED USTEKINUMAB AND ADALIMUMAB RESPONDERS HAVE SIMILAR OUTCOMES AS EARLY RESPONDERS IN BIOLOGIC-NAIVE CROHN'S DISEASE
    Narula, Neeraj
    Wong, Emily C.
    Dulai, Parambir S.
    Marshall, John K.
    Jairath, Vipul
    Reinisch, Walter
    GASTROENTEROLOGY, 2024, 166 (05) : S1430 - S1430
  • [50] Opiate Use in Inflammatory Bowel Disease (IBD): Impact on Biologic/Immune Modulator Utilization and Associated Outcomes
    Vamadevan, Arunan S.
    Volfson, Ariy
    Khan, Sundas
    McCullagh, Lauren
    Akerman, Meredith
    Sultan, Keith
    GASTROENTEROLOGY, 2013, 144 (05) : S429 - S429
12345